USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Development and Characterization of Bio-inert UNCD films for…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
91110
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
0912855
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Advanced Diamond TechNologies, Inc.
48 E. Belmont Drive Romeoville, IL 60446-1764
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: SBIR Phase I: Development and Characterization of Bio-inert UNCD films for Implantable Devices to Eliminate Blood Clotting
Agency: NSF
Contract: 0912855
Award Amount: $99,852.00
 

Abstract:

This Small Business Innovation Research Phase I project will investigate UNCDýý, a nanocrystalline from of smooth, thin diamond, as an anti-thrombotic coating for implantable medical devices. One of the largest problem with implantable circulatory assist devices such as artificial hearts and vascular assist devices (VADs) is the need to treat patients with anticoagulants to avoid blood clots within the devices and to avoid heart attack, stroke, and death that may occur if the anticoagulation dosage is not right. Previous work on diamond and diamond-like carbon (DLC) has demonstrated reduced interactivity between the coating and human blood clotting factors. The use of UNCD however, with its overall biochemical and electrochemical inertness, extreme durability to wear, and very low surface roughness, will extend the advantages previously demonstrated with other carbon materials. The broader impacts of this research are the potential reduction or elimination of anticoagulants for patients with implanted medical devices, making a much larger patient population eligible for advanced devices such as heart pumps, and enabling the use of these devices for new applications. UNCD coatings on the blood contacting surfaces of these and similar devices has the potential to eliminate the need for anticoagulation or to reduce it to so low a dose that the risk of fatal bleeding can be eliminated. The reduction in prescription costs alone could pay for this investment many times over. Fundamental work will also shed light on the effects of dynamic blood flow, variations in surface chemistry and morphology on the thrombus/clot formation. This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).

Principal Investigator:

John A. Carlisle
PhD
8152930900
carlisle@thindiamond.com

Business Contact:

John A. Carlisle
PhD
8152930900
carlisle@thindiamond.com
Small Business Information at Submission:

ADVANCED DIAMOND TECHNOLOGIES
429 B Weber Road # 286 Romeoville, IL 60446

EIN/Tax ID: 200551423
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No